You are here

AbbVie

In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset

In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset

Fierce Pharma

Multiple Myeloma

Flag link:

AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences

AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences

Best Stocks

Caribou Biosciences

Flag link:

AbbVie Ends I-Mab Partnership for CD47 Antibody Compounds, Products

AbbVie Ends I-Mab Partnership for CD47 Antibody Compounds, Products

BioSpace

I-Mab Biopharma

Flag link:

Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar

Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar

BioSpace

Flag link:

Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox

Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox

Fierce Pharma

Revance Therapeutics

Flag link:

With trial win, AbbVie cues up Botox for another cosmetic indication

With trial win, AbbVie cues up Botox for another cosmetic indication

Fierce Pharma

platysma prominence

Flag link:

AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program

AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program

BioSpace

Harpoon Therapeutics

Multiple Myeloma

Flag link:

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial

BioSpace

Crohn's Disease

clinical trials

Flag link:

GSK spends big on new RSV vax commercials, but it's an AbbVie clean sweep as August's top pharma drug ad spender

GSK spends big on new RSV vax commercials, but it's an AbbVie clean sweep as August's top pharma drug ad spender

Fierce Pharma

DTC advertising

pharma marketing

Flag link:

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

BioSpace

Crohn's Disease

Flag link:

AbbVie in line for hefty payout after Takeda breached supply contract on Lupron

AbbVie in line for hefty payout after Takeda breached supply contract on Lupron

Fierce Pharma

Flag link:

Biden administration lists 10 drugs for Medicare price negotiation

Biden administration lists 10 drugs for Medicare price negotiation

Medical Marketing and Media

Bristol Myers Squibb

Boehringer Ingelheim

Flag link:

AbbVie Removes Two Early-Stage Cancer Assets from Pipeline

AbbVie Removes Two Early-Stage Cancer Assets from Pipeline

BioSpace

antibody-drug conjugate

Flag link:

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

Pharma Voice

Tessara Therapeutics

Flagship Pioneering

Michael Severino

Flag link:

Amgen's hyped Humira biosimilar fritters away its exclusivity advantage

Amgen's hyped Humira biosimilar fritters away its exclusivity advantage

Fierce Pharma

Flag link:

Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance

Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance

Fierce Pharma

Flag link:

Biosimilar makers split strategies in bid to take on top-selling Humira

Biosimilar makers split strategies in bid to take on top-selling Humira

BioPharma Dive

Boehringer Ingelheim

Flag link:

AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis

AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis

Fierce Pharma

Boehringer Ingelheim

Flag link:

Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment

Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment

Fierce Pharma

Teva Pharmaceutical

drug manufacturing

Flag link:

Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease

Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease

BioSpace

neurodegenerative disease

Alzheimer's disease

Axsome Therapeutics

BrainStorm Cell Therapeutics

Seelos Therapeutics

Parkinson's Disease

Mitsubishi Tanabe Pharma

Huntington's disease

Prilenia Therapeutics

Flag link:

Pages